Update shared on29 Aug 2025
Fair value Increased 4.84%Analysts have raised their price target for Veeva Systems to $314.71, citing strong Q2 “beat and raise” results, momentum in both Commercial and R&D segments, successful Vault CRM rollouts with major pharma clients, and ongoing market share gains in life sciences CRM.
Analyst Commentary
- Bullish analysts highlighted Veeva's strong “beat and raise” Q2 results, with both subscription and services revenues growing solidly year-over-year, driven by performance in both Commercial and R&D technology segments.
- Commitment and successful live rollout of Vault CRM among the top 20 pharma customers—including a key milestone go-live with GSK—are viewed as critical in maintaining and expanding Veeva’s leading CRM market share during the CRM migration.
- Ongoing strength in Veeva's Crossix and improving R&D subscription growth are supporting positive outlooks for continued momentum and market share gains in the bio-pharma industry.
- Several analysts noted that while guidance and business momentum remain strong, near-term billings performance has underwhelmed expectations and “the bar was arguably higher” following prior outperformance, leading to some cautious or neutral stances.
- Bullish analysts continue to see Veeva as well positioned against Salesforce in the life sciences CRM market, citing additional top pharma commitments, early success with AI initiatives, and solid trends in large pharma end-markets.
What's in the News
- Merck has committed to Veeva Vault CRM to support major upcoming product launches, leveraging Vault CRM’s global capabilities for compliance and commercial execution.
- Veeva Systems has been added to multiple Russell value-oriented indices, including Russell 3000E, 1000, Midcap, and Small Cap Value benchmarks, reflecting its inclusion in a broad range of value index products.
- Veeva expanded its collaboration with Amazon Web Services, using AWS as cloud infrastructure for Veeva Vault applications and integrating AWS solutions to enhance CRM, data, and AI-driven offerings tailored for life sciences.
- Grunenthal is implementing Veeva RIM to streamline global regulatory information management, improving compliance, efficiency, and data oversight in regulatory processes.
- Over 50 medtech companies, including top global firms, adopted Veeva Clinical Platform applications, resulting in faster study builds and reduced duplicate trial documentation, enhancing regulatory compliance and operational efficiency.
Valuation Changes
Summary of Valuation Changes for Veeva Systems
- The Consensus Analyst Price Target has risen slightly from $300.78 to $314.71.
- The Net Profit Margin for Veeva Systems has risen from 29.68% to 31.54%.
- The Future P/E for Veeva Systems has fallen from 52.33x to 49.29x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.